<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322474</url>
  </required_header>
  <id_info>
    <org_study_id>8-5</org_study_id>
    <nct_id>NCT04322474</nct_id>
  </id_info>
  <brief_title>Russian National Registry of LAAO</brief_title>
  <official_title>Russian National Registry of Left Atrial Appendage Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Center for Preventive Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Research Center for Preventive Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first Russian registry presents data from two hundred consecutive patients with
      nonvalvular atrial fibrillation, who undergone left atrial appendage occlusion (LAAO) using
      the Watchman device and the Amplatzer cardiac plug. This government-funded catheter-based
      LAAO program was started in September 2015 and was completed in December 2017. Data
      collection was finished in December 2018. Five clinics agreed to participate in the study.

      Patients' baseline characteristics, procedure, and follow up data were collected according to
      established registry protocol. Patients were followed at 45 days, 3, 6 and 12 months after
      enrollment. At each follow-up visit, the data regarding clinical events and healthcare
      utilization was collected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2015</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 30, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Procedure-related major adverse events (pericardial effusion, cardiac tamponade, device embolization, procedure/device-related death)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The composite of thromboembolic events, device thrombosis, hemorrhagic events, unexplained death</measure>
    <time_frame>12 months</time_frame>
    <description>Primary efficacy endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure success rate</measure>
    <time_frame>intraprocedural</time_frame>
    <description>successful left atrial appendage occluder implantation rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peridevice leakage</measure>
    <time_frame>6 months</time_frame>
    <description>incidence rates of significant (≥5mm) leakage</description>
  </secondary_outcome>
  <enrollment type="Actual">200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Catheter-based left atrial appendage occlusion</intervention_name>
    <description>Catheter-based implantation of left atrial appendage occluder</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Nonvalvular atrial fibrillation patients with a high risk of thromboembolic and
        haemorrhagic events
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥18 years nonvalvular atrial fibrillation,

          -  CHA2DS2VASc ≥2,

          -  high risk of hemorrhagic events,

          -  non-compliance with pharmacological anticoagulant therapy

        Exclusion Criteria:

          -  significant mitral valve disease,

          -  left ventricular ejection fraction &lt;35%,

          -  the tendency to systemic thrombosis,

          -  severe co-morbidities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karapet Davtyan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Research Center for Preventive Medicine</affiliation>
  </overall_official>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>left atrial appendage</keyword>
  <keyword>stroke prevention</keyword>
  <keyword>occluder</keyword>
  <keyword>Watchman device</keyword>
  <keyword>Amplatzer Cardiac Plug</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

